Biogen Idec prices its newly approved hemophilia drug

April 18, 2014 7:55 PM

31 0

Biogen Idec Inc. has priced its newly approved hemophilia B drug Alprolix at a level that puts it at cost parity with drugs already on the US market to control and prevent bleeding, a representative of the Cambridge drug maker said Friday.

The “wholesale acquisition cost” of Alprolix -- an estimate of the price paid by bulk purchasers -- is $2.85 per international unit. While the cost is higher than the $1.19 charged by rival Pfizer Inc. for the leading competing drug, Benefix, hemophilia B patients only have to take the long-acting B...

Read more

To category page